Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
June 1, 2017
Corium to Present at the Jefferies 2017 Global Healthcare Conference
MENLO PARK, Calif., June 01, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the Jefferi…


May 31, 2017
Corium Announces Closing of Follow-On Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., May 31, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has closed its previously announced underwritten public offering of 6,440,000 shares of…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2